Five daily doses of canagliflozin (300 mg) will be administered to healthy volunteers.
Pharmacodynamic responses to canagliflozin will be assessed both at 2 days and 6 days after
administration of the first dose of canagliflozin. A genome-wide association study (GWAS)
will be conducted to search for genetic variants that are associated with each of the
pharmacodynamic responses to canagliflozin.